SCHEMBL3413587

SCHEMBL3413587

COC(=O)c1cc(F)cc(Br)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.44
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
ALDH1A1 P00352 3/20 0.38
NOTUM Q6P988 2/20 0.38
TSHR P16473 2/20 0.38
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA7 P43166 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296704 1.00 SOS1 (0.44) SOS1SLC6A4SLC6A3SMN1; SMN2NPC1
SCHEMBL31055681 0.84 SOS1 (0.49) SOS1SLC6A4SLC6A3SMN1; SMN2NPC1
SCHEMBL19971599 0.84 SOS1 (0.49) SOS1SLC6A4SLC6A3SMN1; SMN2NPC1
SCHEMBL31283849 0.82 SOS1 (0.44) SOS1SLC6A4SLC6A3ALDH1A1NOTUM
SCHEMBL16048883 0.82 SOS1 (0.44) SOS1SLC6A4SLC6A3ALDH1A1NOTUM
SCHEMBL14719381 0.81 SLC6A4 (0.41) SOS1SLC6A4SLC6A3SMN1; SMN2NPC1
SCHEMBL21621554 0.81 SLC6A4 (0.45) SOS1SLC6A4SLC6A3SMN1; SMN2NPC1
SCHEMBL20903073 0.81 XDH (0.49) SOS1SMN1; SMN2ALDH1A1MAPTCA12
SCHEMBL18878112 0.81 CES2 (0.44) SLC6A4SLC6A3SMN1; SMN2NPC1CASP3
SCHEMBL935778 0.81 HSD17B10 (0.49) SOS1SLC6A3ALDH1A1NOTUMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025262297-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 WO disclosed
WO-2025137158-A1 DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
WO-2025122491-A1 FUSED BICYCLIC ARYL COMPOUNDS FOR BORON NEUTRON CAPTURE THERAPY AVIKO RADIOPHARMACEUTICALS, LLC (US) 2025-06-12 WO disclosed
EP-4561563-A2 TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF Ensem Therapeutics, Inc. (US) 2025-06-04 EP disclosed
CN-119947718-A Tricyclic aryl derivatives, and compositions and methods thereof 昂胜医疗科技公司 2025-05-06 CN disclosed
WO-2025038462-A2 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2025-02-20 WO disclosed
WO-2024182778-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-09-06 WO disclosed
US-20240270757-A1 SPIROCYCLIC COMPOUNDS ASTRAZENECA AB (SE) 2024-08-15 US disclosed
EP-4402143-A1 SPIROCYCLIC COMPOUNDS Astrazeneca AB (SE) 2024-07-24 EP disclosed
CN-117916241-A Spiro compounds 阿斯利康(瑞典)有限公司 2024-04-19 CN disclosed
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2019-09-12 US disclosed
US-10144745-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-12-04 US disclosed
US-9938302-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-04-10 US disclosed
US-20170333443-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2017-11-23 US disclosed
US-20170334932-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2017-11-23 US disclosed
WO-2017201069-A1 OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS BIOTHERYX, INC. (US) 2017-11-23 WO disclosed
US-8362030-B2 Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2013-01-29 US disclosed
US-20110053911-A1 TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2011-03-03 US disclosed
EP-2265611-A1 TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2010-12-29 EP disclosed
WO-2009112832-A1 TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10144745-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, CKS1B SOS1 2058/4885SLC6A4 4761/4885SLC6A3 4868/4885
US-20110053911-A1 TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP2, PARP11 SOS1 3429/4885SLC6A4 4031/4885SLC6A3 3979/4885
US-20240270757-A1 SPIROCYCLIC COMPOUNDS PKD1, PKD2, CCNI SOS1 1517/4885SLC6A4 3598/4885SLC6A3 2609/4885
US-20170333443-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B SOS1 2058/4885SLC6A4 4761/4885SLC6A3 4868/4885
US-20170334932-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B SOS1 2058/4885SLC6A4 4761/4885SLC6A3 4868/4885
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B SOS1 2058/4885SLC6A4 4761/4885SLC6A3 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.